Skip to content

China Registry of Non-disabling Ischemic Cerebrovascular Events

China Registry of Non-disabling Ischemic Cerebrovascular Events: A Prospective Multi-center, National Registry Trail

Status
UNKNOWN
Phases
Unknown
Study type
Observational
Source
ClinicalTrials.gov
Registry ID
NCT03079674
Acronym
CR-NICE
Enrollment
10000
Registered
2017-03-14
Start date
2017-06-01
Completion date
2020-02-01
Last updated
2017-05-11

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Minor Stroke, Transient Ischemic Attack

Keywords

transient Ischemic Attack, minor Stroke, non-disabling ischemic cerebrovascular events, biomarker, epidemiology, prognosis

Brief summary

The burden of non-disabling ischemic cerebrovascular events (NICE) is significantly increased. In order to achieve accurate risk stratification and effective treatments, developing new diagnostic, therapeutic, and prognostic strategies is indispensable. Chinese registry of NICE is a national multi-center prospective study aimed to explore the epidemiology, new biomarkers, risk factors and prognostic models.

Detailed description

The pathophysiology of transient ischemic attack (TIA) and minor stroke is a continuous progression. TIA and minor stroke exhibit the common substantial risk factors for early stroke recurrence and epidemiological characteristic. Since TIA and minor stroke may leave impermanent or mild neurological deficit, they are termed as non-disabling ischemic cerebrovascular disease (NICE). The results of the China Chronic Disease and Risk Factor Surveillance (CCDRFS) 2010 showed that the age-standardized prevalence of TIA is 2.27%. Estimated 23.9 million people may have experienced a TIA in China. The TIA knowing-rate is approximately 3.08% in Chinese adults, only 5.02% received treatment and 4.07% received guideline recommended therapy. The Second China National Stroke Registry (CNSR-II) indicated that minor stroke accounted for 42.23% of all the hospitalized patients of ischemic stroke, which is much higher than that showed in CNSR-I (2007-2008). Thus, it is imperative to develop new strategies to improve the diagnosis, risk prediction and appropriate management of NICE. NICE is an attractive researching area globally. According to the large quantities of NICE patients in China and the low standardized therapeutic rate, the awareness of NICE is largely insufficient. The purpose of the present study is to establish a multi-center national prospective database of NICE, including clinical information and biological samples library and, to further explore the epidemiology, new biomarkers, risk factors, and prognostic models.

Interventions

observational only- no intervention

Sponsors

National Health and Family Planning Commission, P.R.China
CollaboratorOTHER_GOV
Beijing Tiantan Hospital
CollaboratorOTHER
The First Affiliated Hospital of Zhengzhou University
Lead SponsorOTHER

Study design

Observational model
COHORT
Time perspective
PROSPECTIVE

Eligibility

Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
No

Inclusion criteria

1. ≥18 years old 2. elapsed time from last episode to registry \<48 hours

Exclusion criteria

1. patients who refused to participate in the research, and patients who failed to complete the follow-up protocol. 2. patients with malignant tumors, or patients with severe liver or kidney disease, whose life expectancy is less than 1 year. 3. patients who received endovascular or thrombolytic therapy.

Design outcomes

Primary

MeasureTime frameDescription
Death3 monthsDeath from any cause
Stroke recurrence3 monthsIschemic stroke

Secondary

MeasureTime frameDescription
Hemorrhagic stroke3 monthsCerebral hemorrhage and subaraclmoid hemorrhage
Cardiovascular disease3 monthsCoronary heart disease and Angina pectoris
Functional outcome3 monthsModified Rankin Scale ≥3

Countries

China

Contacts

Primary ContactYuming Xu, MD, PhD
xuyuming@zzu.edu.cn86-13903711125
Backup ContactYilong Wang, MD, PhD
yilong528@aliyun.com+86-010-67098350

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026